-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
414 ，2020，1919.
09，2.
86%；44.
96，10.
17%。，20156.
18202019.
72，5。，26（8）；18（）、34；25，122。
09，2.
86%；44.
96，10.
17%。，20156.
18202019.
72，5。，26（8）；18（）、34；25，122。
19，4
331，4//，。//，。，2019、、（）2。
At present, Shanghai Pharmaceuticals is reviewing 18 varieties (31 acceptance numbers) of generic drugs under the new registration classification, which will be deemed to have passed the consistency evaluation after approval for production.
Four of the 18 varieties have not been approved for the listing of generic drugs in the domestic market.
They are mometasone furoate and formoterol fumarate inhalation aerosol, eslicarbazepine acetate tablets, and bromhexine hydrochloride for inhalation.
Solution, sodium tetradecyl sulfate injection.
Among them, mometasone furoate and formoterol fumarate inhalation aerosol and sodium tetradecyl sulfate injection were produced exclusively by Shanghai Pharmaceuticals, and they will most likely win the first imitation.
They are mometasone furoate and formoterol fumarate inhalation aerosol, eslicarbazepine acetate tablets, and bromhexine hydrochloride for inhalation.
Solution, sodium tetradecyl sulfate injection.
Among them, mometasone furoate and formoterol fumarate inhalation aerosol and sodium tetradecyl sulfate injection were produced exclusively by Shanghai Pharmaceuticals, and they will most likely win the first imitation.
New registration classification of generic drugs under review by Shanghai Pharmaceuticals
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
26 varieties have been reviewed! 34 consistency evaluation varieties are under review
Recently, the official website of NMPA showed that the aripiprazole capsules and aripiprazole tablets of Shanghai Shangyao Zhongxi Pharmaceutical, a subsidiary of Shanghai Pharmaceutical Holdings, passed the consistency evaluation at the same time.
Aripiprazole is a treatment drug for schizophrenia.
According to data from Minnet, the sales of terminal aripiprazole in China's public medical institutions exceeded 1.
1 billion yuan in 2019.
Shanghai Pharmaceutical’s aripiprazole tablets were the third to be reviewed, and aripiprazole capsules were the first to be reviewed of the same variety.
Aripiprazole is a treatment drug for schizophrenia.
According to data from Minnet, the sales of terminal aripiprazole in China's public medical institutions exceeded 1.
1 billion yuan in 2019.
Shanghai Pharmaceutical’s aripiprazole tablets were the third to be reviewed, and aripiprazole capsules were the first to be reviewed of the same variety.
Up to now, Shanghai Pharmaceuticals has 26 varieties (34 product regulations) passed/deemed to have passed the consistency evaluation, of which 25 varieties have been evaluated by the consistency evaluation supplementary application method.
Among the 26 varieties, there are 9 cardiovascular system drugs, 7 nervous system drugs and 4 systemic anti-infective drugs.
Among them, there are 8 varieties of Aripiprazole Capsules, Allopurinol Tablets, Alprazolam Tablets, Telmisartan Tablets, Levonorgestrel Tablets, Ambroxol Hydrochloride Capsules, Hydrochlorothiazide Tablets and Fluoxetine Hydrochloride Capsules For the first review.
Among the 26 varieties, there are 9 cardiovascular system drugs, 7 nervous system drugs and 4 systemic anti-infective drugs.
Among them, there are 8 varieties of Aripiprazole Capsules, Allopurinol Tablets, Alprazolam Tablets, Telmisartan Tablets, Levonorgestrel Tablets, Ambroxol Hydrochloride Capsules, Hydrochlorothiazide Tablets and Fluoxetine Hydrochloride Capsules For the first review.
Shanghai Pharmaceutical passed/deemed passed consistency evaluation varieties
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In addition, Shanghai Pharmaceuticals has 34 supplementary applications for consistency evaluation of generic drugs under review.
Among them, furosemide injection, duloxetine hydrochloride enteric-coated tablets, hydroxychloroquine sulfate tablets, estazolam tablets, carbamazepine tablets, and neostigmine methosulfate injections.
.
.
15 varieties have not been registered Evaluation, Shanghai Pharmaceuticals will compete with a number of pharmaceutical companies for the first evaluation.
Among them, furosemide injection, duloxetine hydrochloride enteric-coated tablets, hydroxychloroquine sulfate tablets, estazolam tablets, carbamazepine tablets, and neostigmine methosulfate injections.
.
.
15 varieties have not been registered Evaluation, Shanghai Pharmaceuticals will compete with a number of pharmaceutical companies for the first evaluation.
Supplementary Application Varieties for Consistency Evaluation of Shanghai Pharmaceuticals in Review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
R & D throws 2 billion! 25 innovative drugs are dazzling
On March 31, Shanghai Pharmaceuticals issued an announcement stating that the B001-A (recombinant anti-CD20 humanized monoclonal antibody injection) clinical trial application developed by the company was accepted by the State Food and Drug Administration.
B001-A is a new recombinant monoclonal antibody product for human use, intended for the treatment of multiple sclerosis.
The global marketed drugs with the same target and the same indication include Roche's Ocrelizumab.
According to data from Mi Nei.
com, the drug 's global sales in 2020 were 4.
326 billion Swiss francs (4.
611 billion US dollars), a year-on-year increase of 24%.
B001-A is a new recombinant monoclonal antibody product for human use, intended for the treatment of multiple sclerosis.
The global marketed drugs with the same target and the same indication include Roche's Ocrelizumab.
According to data from Mi Nei.
com, the drug 's global sales in 2020 were 4.
326 billion Swiss francs (4.
611 billion US dollars), a year-on-year increase of 24%.
In recent years, Shanghai Pharmaceuticals has continued to increase investment in R&D and innovation, and has continuously enriched its innovative product pipeline.
In 2020, Shanghai Pharmaceutical's R&D investment reached 1.
972 billion yuan, a year-on-year increase of 30.
70%, of which research and development expenses were 1.
658 billion yuan, a year-on-year increase of 22.
76%.
In 2020, Shanghai Pharmaceutical's R&D investment reached 1.
972 billion yuan, a year-on-year increase of 30.
70%, of which research and development expenses were 1.
658 billion yuan, a year-on-year increase of 22.
76%.
Shanghai Pharmaceuticals has enriched its innovative drug pipeline with the "self-research + introduction" model.
The innovative drug pipeline has entered the pre-clinical and follow-up research phases with 25 products, of which 15 products have entered the clinical or marketed.
In terms of drug types, there are 14 chemical drugs, 10 therapeutic biological products, 1 Chinese patent medicine, and 22 of them are Class 1 new drugs.
The innovative drug pipeline has entered the pre-clinical and follow-up research phases with 25 products, of which 15 products have entered the clinical or marketed.
In terms of drug types, there are 14 chemical drugs, 10 therapeutic biological products, 1 Chinese patent medicine, and 22 of them are Class 1 new drugs.
Progress of Shanghai Pharmaceutical Innovative Drug Pipeline
From the perspective of research and development progress, I001 (SPH3127 tablets) indications for primary mild and moderate pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension have entered the phase III clinical research phase; Lei Tengshu (I008, I008 -A) AIDS immune abnormal activation, anti-rheumatoid arthritis two Both indications are in phase II clinical research phase; I037 (LT3001 for injection) acute ischemic stroke indication has entered phase II clinical trials in the United States, and phase I clinical trials have been initiated in China.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension have entered the phase III clinical research phase; Lei Tengshu (I008, I008 -A) AIDS immune abnormal activation, anti-rheumatoid arthritis two Both indications are in phase II clinical research phase; I037 (LT3001 for injection) acute ischemic stroke indication has entered phase II clinical trials in the United States, and phase I clinical trials have been initiated in China.
In addition, the fully human anti-PD-1 monoclonal antibody "Prolgolimab injection" of Shanghai Pharmaceutical Bokang License-in in September 2019 has been approved by the State Food and Drug Administration to carry out phase III clinical trials.
Shanghai Pharmaceuticals predicts that by the end of this year, the number of pipelines of the company will enter the 3 word era, and many projects will enter clinical phase III.
Shanghai Pharmaceuticals predicts that by the end of this year, the number of pipelines of the company will enter the 3 word era, and many projects will enter clinical phase III.
Conclusion
According to data, Shanghai Pharmaceuticals is a large-scale pharmaceutical industry group listed in Shanghai and Hong Kong.
Its main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail.
It is one of the few pharmaceutical listings in China that has a leading position in both pharmaceutical products and distribution markets.
the company.
The company has formulated an innovation and transformation strategy, and in recent years has firmly moved towards a research and development-oriented pharmaceutical enterprise driven by technological innovation .
Its main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail.
It is one of the few pharmaceutical listings in China that has a leading position in both pharmaceutical products and distribution markets.
the company.
The company has formulated an innovation and transformation strategy, and in recent years has firmly moved towards a research and development-oriented pharmaceutical enterprise driven by technological innovation .
In 2020, the company's pharmaceutical industry sales revenue was 23.
743 billion yuan, a year-on-year increase of 1.
08%.
Among them, the sales revenue of 60 key varieties was 13.
318 billion yuan, a year-on-year decrease of 1.
55%.
The main reason was that they were affected by the epidemic at the beginning of the year, but gradually stabilized and rebounded in the second quarter.
The company's focus strategy on large products, with "one product, one policy" as the starting point, the number of products with annual industrial sales revenue of over 100 million yuan has increased from 35 in 2019 to 42 in 2020.
The products cover the cardiovascular, digestive, and digestive systems.
Immune metabolism, systemic anti-infection, neuropsychiatric and anti-tumor fields.
743 billion yuan, a year-on-year increase of 1.
08%.
Among them, the sales revenue of 60 key varieties was 13.
318 billion yuan, a year-on-year decrease of 1.
55%.
The main reason was that they were affected by the epidemic at the beginning of the year, but gradually stabilized and rebounded in the second quarter.
The company's focus strategy on large products, with "one product, one policy" as the starting point, the number of products with annual industrial sales revenue of over 100 million yuan has increased from 35 in 2019 to 42 in 2020.
The products cover the cardiovascular, digestive, and digestive systems.
Immune metabolism, systemic anti-infection, neuropsychiatric and anti-tumor fields.
The company’s R&D investment has continued to grow steadily, ensuring that both new products in the existing R&D product line have been approved and approved for listing, which has provided continuous impetus to the company’s steady and healthy development and has also continuously improved the company’s core competitiveness.
Data source: Mi Nei.
com database, company announcement
com database, company announcement
Note: The statistics are as of April 7, if there are any omissions, please correct me!
Medical Network News on April 14 A few days ago, Shanghai Pharmaceuticals announced its 2020 results, operating income of 191.
09 billion yuan, a year-on-year increase of 2.
86%; net profit of 4.
496 billion yuan, a year-on-year increase of 10.
17%.
The company insists on innovation and transformation, and its R&D investment has more than tripled in five years from 618 million yuan in 2015 to 1.
972 billion yuan in 2020.
At present, Shanghai Pharmaceuticals has already reviewed 26 varieties (8 as the first); 18 generic drugs (new classification) applications for marketing and 34 additional applications for consistency evaluation of varieties are under review; 25 innovative drugs are in pre-clinical and In the follow-up research phase, there are 22 new drugs in class 1.
09 billion yuan, a year-on-year increase of 2.
86%; net profit of 4.
496 billion yuan, a year-on-year increase of 10.
17%.
The company insists on innovation and transformation, and its R&D investment has more than tripled in five years from 618 million yuan in 2015 to 1.
972 billion yuan in 2020.
At present, Shanghai Pharmaceuticals has already reviewed 26 varieties (8 as the first); 18 generic drugs (new classification) applications for marketing and 34 additional applications for consistency evaluation of varieties are under review; 25 innovative drugs are in pre-clinical and In the follow-up research phase, there are 22 new drugs in class 1.
19 new products are on the road, 4 major varieties are the first to imitate
On March 31, Hefeng Pharmaceutical, a subsidiary of Shanghai Pharmaceuticals, entered the administrative examination and approval stage with the imitation of the 4 types of citrate coffee/coffee/injection for production, and the approval will be imminent.
Citrate coffee/coffee/yin injection is a pediatric drug used to treat primary apnea in premature newborns.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2019 exceeded 200 million yuan.
Citrate coffee/coffee/yin injection is a pediatric drug used to treat primary apnea in premature newborns.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2019 exceeded 200 million yuan.
At present, Shanghai Pharmaceuticals is reviewing 18 varieties (31 acceptance numbers) of generic drugs under the new registration classification, which will be deemed to have passed the consistency evaluation after approval for production.
Four of the 18 varieties have not been approved for the listing of generic drugs in the domestic market.
They are mometasone furoate and formoterol fumarate inhalation aerosol, eslicarbazepine acetate tablets, and bromhexine hydrochloride for inhalation.
Solution, sodium tetradecyl sulfate injection.
Among them, mometasone furoate and formoterol fumarate inhalation aerosol and sodium tetradecyl sulfate injection were produced exclusively by Shanghai Pharmaceuticals, and they will most likely win the first imitation.
They are mometasone furoate and formoterol fumarate inhalation aerosol, eslicarbazepine acetate tablets, and bromhexine hydrochloride for inhalation.
Solution, sodium tetradecyl sulfate injection.
Among them, mometasone furoate and formoterol fumarate inhalation aerosol and sodium tetradecyl sulfate injection were produced exclusively by Shanghai Pharmaceuticals, and they will most likely win the first imitation.
New registration classification of generic drugs under review by Shanghai Pharmaceuticals
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
26 varieties have been reviewed! 34 consistency evaluation varieties are under review
Recently, the official website of NMPA showed that the aripiprazole capsules and aripiprazole tablets of Shanghai Shangyao Zhongxi Pharmaceutical, a subsidiary of Shanghai Pharmaceutical Holdings, passed the consistency evaluation at the same time.
Aripiprazole is a treatment drug for schizophrenia.
According to data from Minnet, the sales of terminal aripiprazole in China's public medical institutions exceeded 1.
1 billion yuan in 2019.
Shanghai Pharmaceutical’s aripiprazole tablets were the third to be reviewed, and aripiprazole capsules were the first to be reviewed of the same variety.
Aripiprazole is a treatment drug for schizophrenia.
According to data from Minnet, the sales of terminal aripiprazole in China's public medical institutions exceeded 1.
1 billion yuan in 2019.
Shanghai Pharmaceutical’s aripiprazole tablets were the third to be reviewed, and aripiprazole capsules were the first to be reviewed of the same variety.
Up to now, Shanghai Pharmaceuticals has 26 varieties (34 product regulations) passed/deemed to have passed the consistency evaluation, of which 25 varieties have been evaluated by the consistency evaluation supplementary application method.
Among the 26 varieties, there are 9 cardiovascular system drugs, 7 nervous system drugs and 4 systemic anti-infective drugs.
Among them, there are 8 varieties of Aripiprazole Capsules, Allopurinol Tablets, Alprazolam Tablets, Telmisartan Tablets, Levonorgestrel Tablets, Ambroxol Hydrochloride Capsules, Hydrochlorothiazide Tablets and Fluoxetine Hydrochloride Capsules For the first review.
Among the 26 varieties, there are 9 cardiovascular system drugs, 7 nervous system drugs and 4 systemic anti-infective drugs.
Among them, there are 8 varieties of Aripiprazole Capsules, Allopurinol Tablets, Alprazolam Tablets, Telmisartan Tablets, Levonorgestrel Tablets, Ambroxol Hydrochloride Capsules, Hydrochlorothiazide Tablets and Fluoxetine Hydrochloride Capsules For the first review.
Shanghai Pharmaceutical passed/deemed passed consistency evaluation varieties
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In addition, Shanghai Pharmaceuticals has 34 supplementary applications for consistency evaluation of generic drugs under review.
Among them, furosemide injection, duloxetine hydrochloride enteric-coated tablets, hydroxychloroquine sulfate tablets, estazolam tablets, carbamazepine tablets, and neostigmine methosulfate injections.
.
.
15 varieties have not been registered Evaluation, Shanghai Pharmaceuticals will compete with a number of pharmaceutical companies for the first evaluation.
Among them, furosemide injection, duloxetine hydrochloride enteric-coated tablets, hydroxychloroquine sulfate tablets, estazolam tablets, carbamazepine tablets, and neostigmine methosulfate injections.
.
.
15 varieties have not been registered Evaluation, Shanghai Pharmaceuticals will compete with a number of pharmaceutical companies for the first evaluation.
Supplementary Application Varieties for Consistency Evaluation of Shanghai Pharmaceuticals in Review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
R & D throws 2 billion! 25 innovative drugs are dazzling
On March 31, Shanghai Pharmaceuticals issued an announcement stating that the B001-A (recombinant anti-CD20 humanized monoclonal antibody injection) clinical trial application developed by the company was accepted by the State Food and Drug Administration.
B001-A is a new recombinant monoclonal antibody product for human use, intended for the treatment of multiple sclerosis.
The global marketed drugs with the same target and the same indication include Roche's Ocrelizumab.
According to data from Mi Nei.
com, the drug 's global sales in 2020 were 4.
326 billion Swiss francs (4.
611 billion US dollars), a year-on-year increase of 24%.
B001-A is a new recombinant monoclonal antibody product for human use, intended for the treatment of multiple sclerosis.
The global marketed drugs with the same target and the same indication include Roche's Ocrelizumab.
According to data from Mi Nei.
com, the drug 's global sales in 2020 were 4.
326 billion Swiss francs (4.
611 billion US dollars), a year-on-year increase of 24%.
In recent years, Shanghai Pharmaceuticals has continued to increase investment in R&D and innovation, and has continuously enriched its innovative product pipeline.
In 2020, Shanghai Pharmaceutical's R&D investment reached 1.
972 billion yuan, a year-on-year increase of 30.
70%, of which research and development expenses were 1.
658 billion yuan, a year-on-year increase of 22.
76%.
In 2020, Shanghai Pharmaceutical's R&D investment reached 1.
972 billion yuan, a year-on-year increase of 30.
70%, of which research and development expenses were 1.
658 billion yuan, a year-on-year increase of 22.
76%.
Shanghai Pharmaceuticals has enriched its innovative drug pipeline with the "self-research + introduction" model.
The innovative drug pipeline has entered the pre-clinical and follow-up research phases with 25 products, of which 15 products have entered the clinical or marketed.
In terms of drug types, there are 14 chemical drugs, 10 therapeutic biological products, 1 Chinese patent medicine, and 22 of them are Class 1 new drugs.
The innovative drug pipeline has entered the pre-clinical and follow-up research phases with 25 products, of which 15 products have entered the clinical or marketed.
In terms of drug types, there are 14 chemical drugs, 10 therapeutic biological products, 1 Chinese patent medicine, and 22 of them are Class 1 new drugs.
Progress of Shanghai Pharmaceutical Innovative Drug Pipeline
From the perspective of research and development progress, I001 (SPH3127 tablets) indications for primary mild and moderate pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension have entered the phase III clinical research phase; Lei Tengshu (I008, I008 -A) AIDS immune abnormal activation, anti-rheumatoid arthritis two Both indications are in phase II clinical research phase; I037 (LT3001 for injection) acute ischemic stroke indication has entered phase II clinical trials in the United States, and phase I clinical trials have been initiated in China.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension have entered the phase III clinical research phase; Lei Tengshu (I008, I008 -A) AIDS immune abnormal activation, anti-rheumatoid arthritis two Both indications are in phase II clinical research phase; I037 (LT3001 for injection) acute ischemic stroke indication has entered phase II clinical trials in the United States, and phase I clinical trials have been initiated in China.
In addition, the fully human anti-PD-1 monoclonal antibody "Prolgolimab injection" of Shanghai Pharmaceutical Bokang License-in in September 2019 has been approved by the State Food and Drug Administration to carry out phase III clinical trials.
Shanghai Pharmaceuticals predicts that by the end of this year, the number of pipelines of the company will enter the 3 word era, and many projects will enter clinical phase III.
Shanghai Pharmaceuticals predicts that by the end of this year, the number of pipelines of the company will enter the 3 word era, and many projects will enter clinical phase III.
Conclusion
According to data, Shanghai Pharmaceuticals is a large-scale pharmaceutical industry group listed in Shanghai and Hong Kong.
Its main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail.
It is one of the few pharmaceutical listings in China that has a leading position in both pharmaceutical products and distribution markets.
the company.
The company has formulated an innovation and transformation strategy, and in recent years has firmly moved towards a research and development-oriented pharmaceutical enterprise driven by technological innovation .
Its main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail.
It is one of the few pharmaceutical listings in China that has a leading position in both pharmaceutical products and distribution markets.
the company.
The company has formulated an innovation and transformation strategy, and in recent years has firmly moved towards a research and development-oriented pharmaceutical enterprise driven by technological innovation .
In 2020, the company's pharmaceutical industry sales revenue was 23.
743 billion yuan, a year-on-year increase of 1.
08%.
Among them, the sales revenue of 60 key varieties was 13.
318 billion yuan, a year-on-year decrease of 1.
55%.
The main reason was that they were affected by the epidemic at the beginning of the year, but gradually stabilized and rebounded in the second quarter.
The company's focus strategy on large products, with "one product, one policy" as the starting point, the number of products with annual industrial sales revenue of over 100 million yuan has increased from 35 in 2019 to 42 in 2020.
The products cover the cardiovascular, digestive, and digestive systems.
Immune metabolism, systemic anti-infection, neuropsychiatric and anti-tumor fields.
743 billion yuan, a year-on-year increase of 1.
08%.
Among them, the sales revenue of 60 key varieties was 13.
318 billion yuan, a year-on-year decrease of 1.
55%.
The main reason was that they were affected by the epidemic at the beginning of the year, but gradually stabilized and rebounded in the second quarter.
The company's focus strategy on large products, with "one product, one policy" as the starting point, the number of products with annual industrial sales revenue of over 100 million yuan has increased from 35 in 2019 to 42 in 2020.
The products cover the cardiovascular, digestive, and digestive systems.
Immune metabolism, systemic anti-infection, neuropsychiatric and anti-tumor fields.
The company’s R&D investment has continued to grow steadily, ensuring that both new products in the existing R&D product line have been approved and approved for listing, which has provided continuous impetus to the company’s steady and healthy development and has also continuously improved the company’s core competitiveness.
Data source: Mi Nei.
com database, company announcement
com database, company announcement
Note: The statistics are as of April 7, if there are any omissions, please correct me!
Medical Network News on April 14 A few days ago, Shanghai Pharmaceuticals announced its 2020 results, operating income of 191.
09 billion yuan, a year-on-year increase of 2.
86%; net profit of 4.
496 billion yuan, a year-on-year increase of 10.
17%.
The company insists on innovation and transformation, and its R&D investment has more than tripled in five years from 618 million yuan in 2015 to 1.
972 billion yuan in 2020.
At present, Shanghai Pharmaceuticals has already reviewed 26 varieties (8 as the first); 18 generic drugs (new classification) applications for marketing and 34 additional applications for consistency evaluation of varieties are under review; 25 innovative drugs are in pre-clinical and In the follow-up research phase, there are 22 new drugs in class 1.
09 billion yuan, a year-on-year increase of 2.
86%; net profit of 4.
496 billion yuan, a year-on-year increase of 10.
17%.
The company insists on innovation and transformation, and its R&D investment has more than tripled in five years from 618 million yuan in 2015 to 1.
972 billion yuan in 2020.
At present, Shanghai Pharmaceuticals has already reviewed 26 varieties (8 as the first); 18 generic drugs (new classification) applications for marketing and 34 additional applications for consistency evaluation of varieties are under review; 25 innovative drugs are in pre-clinical and In the follow-up research phase, there are 22 new drugs in class 1.
19 new products are on the road, 4 major varieties are the first to imitate
19 new products are on the road, 4 major varieties are the first to imitate On March 31, Hefeng Pharmaceutical, a subsidiary of Shanghai Pharmaceuticals, entered the administrative examination and approval stage with the imitation of the 4 types of citrate coffee/coffee/injection for production, and the approval will be imminent.
Citrate coffee/coffee/yin injection is a pediatric drug used to treat primary apnea in premature newborns.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2019 exceeded 200 million yuan.
Hospital hospital hospitalCitrate coffee/coffee/yin injection is a pediatric drug used to treat primary apnea in premature newborns.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2019 exceeded 200 million yuan.
At present, Shanghai Pharmaceuticals is reviewing 18 varieties (31 acceptance numbers) of generic drugs under the new registration classification, which will be deemed to have passed the consistency evaluation after approval for production.
Four of the 18 varieties have not been approved for the listing of generic drugs in the domestic market.
They are mometasone furoate and formoterol fumarate inhalation aerosol, eslicarbazepine acetate tablets, and bromhexine hydrochloride for inhalation.
Solution, sodium tetradecyl sulfate injection.
Among them, mometasone furoate and formoterol fumarate inhalation aerosol and sodium tetradecyl sulfate injection were produced exclusively by Shanghai Pharmaceuticals, and they will most likely win the first imitation.
They are mometasone furoate and formoterol fumarate inhalation aerosol, eslicarbazepine acetate tablets, and bromhexine hydrochloride for inhalation.
Solution, sodium tetradecyl sulfate injection.
Among them, mometasone furoate and formoterol fumarate inhalation aerosol and sodium tetradecyl sulfate injection were produced exclusively by Shanghai Pharmaceuticals, and they will most likely win the first imitation.
New registration classification of generic drugs under review by Shanghai Pharmaceuticals
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
26 varieties have been reviewed! 34 consistency evaluation varieties are under review
26 varieties have been reviewed! 34 consistency evaluation varieties are under review Recently, the official website of NMPA showed that the aripiprazole capsules and aripiprazole tablets of Shanghai Shangyao Zhongxi Pharmaceutical, a subsidiary of Shanghai Pharmaceutical Holdings, passed the consistency evaluation at the same time.
Aripiprazole is a treatment drug for schizophrenia.
According to data from Minnet, the sales of terminal aripiprazole in China's public medical institutions exceeded 1.
1 billion yuan in 2019.
Shanghai Pharmaceutical’s aripiprazole tablets were the third to be reviewed, and aripiprazole capsules were the first to be reviewed of the same variety.
Aripiprazole is a treatment drug for schizophrenia.
According to data from Minnet, the sales of terminal aripiprazole in China's public medical institutions exceeded 1.
1 billion yuan in 2019.
Shanghai Pharmaceutical’s aripiprazole tablets were the third to be reviewed, and aripiprazole capsules were the first to be reviewed of the same variety.
Up to now, Shanghai Pharmaceuticals has 26 varieties (34 product regulations) passed/deemed to have passed the consistency evaluation, of which 25 varieties have been evaluated by the consistency evaluation supplementary application method.
Among the 26 varieties, there are 9 cardiovascular system drugs, 7 nervous system drugs and 4 systemic anti-infective drugs.
Among them, there are 8 varieties of Aripiprazole Capsules, Allopurinol Tablets, Alprazolam Tablets, Telmisartan Tablets, Levonorgestrel Tablets, Ambroxol Hydrochloride Capsules, Hydrochlorothiazide Tablets and Fluoxetine Hydrochloride Capsules For the first review.
Among the 26 varieties, there are 9 cardiovascular system drugs, 7 nervous system drugs and 4 systemic anti-infective drugs.
Among them, there are 8 varieties of Aripiprazole Capsules, Allopurinol Tablets, Alprazolam Tablets, Telmisartan Tablets, Levonorgestrel Tablets, Ambroxol Hydrochloride Capsules, Hydrochlorothiazide Tablets and Fluoxetine Hydrochloride Capsules For the first review.
Shanghai Pharmaceutical passed/deemed passed consistency evaluation varieties
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In addition, Shanghai Pharmaceuticals has 34 supplementary applications for consistency evaluation of generic drugs under review.
Among them, furosemide injection, duloxetine hydrochloride enteric-coated tablets, hydroxychloroquine sulfate tablets, estazolam tablets, carbamazepine tablets, and neostigmine methosulfate injections.
.
.
15 varieties have not been registered Evaluation, Shanghai Pharmaceuticals will compete with a number of pharmaceutical companies for the first evaluation.
Among them, furosemide injection, duloxetine hydrochloride enteric-coated tablets, hydroxychloroquine sulfate tablets, estazolam tablets, carbamazepine tablets, and neostigmine methosulfate injections.
.
.
15 varieties have not been registered Evaluation, Shanghai Pharmaceuticals will compete with a number of pharmaceutical companies for the first evaluation.
Supplementary Application Varieties for Consistency Evaluation of Shanghai Pharmaceuticals in Review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
R & D throws 2 billion! 25 innovative drugs are dazzling
R & D throws 2 billion! 25 innovative drugs are dazzling On March 31, Shanghai Pharmaceuticals issued an announcement stating that the B001-A (recombinant anti-CD20 humanized monoclonal antibody injection) clinical trial application developed by the company was accepted by the State Food and Drug Administration.
B001-A is a new recombinant monoclonal antibody product for human use, intended for the treatment of multiple sclerosis.
The global marketed drugs with the same target and the same indication include Roche's Ocrelizumab.
According to data from Mi Nei.
com, the drug 's global sales in 2020 were 4.
326 billion Swiss francs (4.
611 billion US dollars), a year-on-year increase of 24%.
Medicine, medicine, medicineB001-A is a new recombinant monoclonal antibody product for human use, intended for the treatment of multiple sclerosis.
The global marketed drugs with the same target and the same indication include Roche's Ocrelizumab.
According to data from Mi Nei.
com, the drug 's global sales in 2020 were 4.
326 billion Swiss francs (4.
611 billion US dollars), a year-on-year increase of 24%.
In recent years, Shanghai Pharmaceuticals has continued to increase investment in R&D and innovation, and has continuously enriched its innovative product pipeline.
In 2020, Shanghai Pharmaceutical's R&D investment reached 1.
972 billion yuan, a year-on-year increase of 30.
70%, of which research and development expenses were 1.
658 billion yuan, a year-on-year increase of 22.
76%.
Medicine Medicine MedicineIn 2020, Shanghai Pharmaceutical's R&D investment reached 1.
972 billion yuan, a year-on-year increase of 30.
70%, of which research and development expenses were 1.
658 billion yuan, a year-on-year increase of 22.
76%.
Shanghai Pharmaceuticals has enriched its innovative drug pipeline with the "self-research + introduction" model.
The innovative drug pipeline has entered the pre-clinical and follow-up research phases with 25 products, of which 15 products have entered the clinical or marketed.
In terms of drug types, there are 14 chemical drugs, 10 therapeutic biological products, 1 Chinese patent medicine, and 22 of them are Class 1 new drugs.
The innovative drug pipeline has entered the pre-clinical and follow-up research phases with 25 products, of which 15 products have entered the clinical or marketed.
In terms of drug types, there are 14 chemical drugs, 10 therapeutic biological products, 1 Chinese patent medicine, and 22 of them are Class 1 new drugs.
Progress of Shanghai Pharmaceutical Innovative Drug Pipeline
From the perspective of research and development progress, I001 (SPH3127 tablets) indications for primary mild and moderate pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension have entered the phase III clinical research phase; Lei Tengshu (I008, I008 -A) AIDS immune abnormal activation, anti-rheumatoid arthritis two Both indications are in phase II clinical research phase; I037 (LT3001 for injection) acute ischemic stroke indication has entered phase II clinical trials in the United States, and phase I clinical trials have been initiated in China.
pharmnet. com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension have entered the phase III clinical research phase; Lei Tengshu (I008, I008 -A) AIDS immune abnormal activation, anti-rheumatoid arthritis two Both indications are in phase II clinical research phase; I037 (LT3001 for injection) acute ischemic stroke indication has entered phase II clinical trials in the United States, and phase I clinical trials have been initiated in China.
com.
cn/pharmnet/200610/hbp/" target="_blank">Hypertensionpharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank"> hypertension hypertension
In addition, the fully human anti-PD-1 monoclonal antibody "Prolgolimab injection" of Shanghai Pharmaceutical Bokang License-in in September 2019 has been approved by the State Food and Drug Administration to carry out phase III clinical trials.
Shanghai Pharmaceuticals predicts that by the end of this year, the number of pipelines of the company will enter the 3 word era, and many projects will enter clinical phase III.
Shanghai Pharmaceuticals predicts that by the end of this year, the number of pipelines of the company will enter the 3 word era, and many projects will enter clinical phase III.
Conclusion
Conclusion According to data, Shanghai Pharmaceuticals is a large-scale pharmaceutical industry group listed in Shanghai and Hong Kong.
Its main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail.
It is one of the few pharmaceutical listings in China that has a leading position in both pharmaceutical products and distribution markets.
the company.
The company has formulated an innovation and transformation strategy, and in recent years has firmly moved towards a research and development-oriented pharmaceutical enterprise driven by technological innovation .
Enterprise business enterpriseIts main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail.
It is one of the few pharmaceutical listings in China that has a leading position in both pharmaceutical products and distribution markets.
the company.
The company has formulated an innovation and transformation strategy, and in recent years has firmly moved towards a research and development-oriented pharmaceutical enterprise driven by technological innovation .
In 2020, the company's pharmaceutical industry sales revenue was 23.
743 billion yuan, a year-on-year increase of 1.
08%.
Among them, the sales revenue of 60 key varieties was 13.
318 billion yuan, a year-on-year decrease of 1.
55%.
The main reason was that they were affected by the epidemic at the beginning of the year, but gradually stabilized and rebounded in the second quarter.
The company's focus strategy on large products, with "one product, one policy" as the starting point, the number of products with annual industrial sales revenue of over 100 million yuan has increased from 35 in 2019 to 42 in 2020.
The products cover the cardiovascular, digestive, and digestive systems.
Immune metabolism, systemic anti-infection, neuropsychiatric and anti-tumor fields.
743 billion yuan, a year-on-year increase of 1.
08%.
Among them, the sales revenue of 60 key varieties was 13.
318 billion yuan, a year-on-year decrease of 1.
55%.
The main reason was that they were affected by the epidemic at the beginning of the year, but gradually stabilized and rebounded in the second quarter.
The company's focus strategy on large products, with "one product, one policy" as the starting point, the number of products with annual industrial sales revenue of over 100 million yuan has increased from 35 in 2019 to 42 in 2020.
The products cover the cardiovascular, digestive, and digestive systems.
Immune metabolism, systemic anti-infection, neuropsychiatric and anti-tumor fields.
The company’s R&D investment has continued to grow steadily, ensuring that both new products in the existing R&D product line have been approved and approved for listing, which has provided continuous impetus to the company’s steady and healthy development and has also continuously improved the company’s core competitiveness.
Data source: Mi Nei.
com database, company announcement
com database, company announcement
Note: The statistics are as of April 7, if there are any omissions, please correct me!
